Reports Q1 revenue $741.5M, consensus $720.7M. "Dexcom is off to a great start in 2023, executing on several key initiatives including the launch of Dexcom G7 in the United States," said Kevin Sayer, Dexcom’s chairman, president and CEO. "Given the strength of our first quarter results and an expanding market opportunity with new CGM coverage now available, we are pleased to raise our 2023 revenue guidance."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DXCM:
- DXCM Upcoming Earnings Report: What to Expect?
- DexCom price target raised to $132 from $126 at BTIG
- DexCom commends expansion of CGM Medicare to diabetics using all insulin types
- DexCom upgraded to Strong Buy from Outperform at Raymond James
- Fly Insider: Kohl’s, 89Bio among week’s notable insider trades